psychosomatics | CARLAT PUBLISHING

Expert Q&A

Migraine in the Psychiatric Patient

November 9, 2023

Lex Denysenko, MD.

Assistant Professor of Psychiatry, Thomas Jefferson University Hospitals; Director, Behavioral Headache Medicine, Jefferson Headache Center.

Dr. Denysenko has no financial relationships with companies related to this material.

Lex Denysenko shows us how to personalize psychiatric medications for patients with migraines. Learn which antidepressants are best, where propranolol fits, and why valproate (Depakote) is not always preferred.

Clinical Update

Psychiatric Consultation to Children and Adolescents on Pediatric Units: A Primer

August 1, 2023

Jessica E. Becker, MD, MPH. and Joshua Smith, MD.

Jessica E. Becker, MD, MPH. Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, NYU Langone Health, New York, NY.

Joshua Smith, MD. Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN.

Dr. Becker is an awardee of the American Academy of Child and Adolescent Psychiatry (AACAP) Junior Investigator Award, which is funded by AACAP and industry sponsors. Relevant financial relationships listed for the author have been mitigated.

Dr. Smith has no financial relationships with companies related to this material.

Pediatric consultation-liaison (C-L) psychiatry is a field that combines psychiatry, pediatrics, and child development. We’ll give you pointers on how to manage pediatric C-L psychiatry consults, with specific recommendations for different age groups.

Clinical Update

Music for Sleep

April 14, 2023

Jesse Koskey, MD.

Jesse Koskey, MD. Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, UC Davis Health, Sacramento, CA.

Dr. Koskey has no financial relationships with companies related to this material.

An alternative to hypnotics with a surprising effect size.

Expert Q&A

Cardiovascular Psychiatry: Part 1

April 14, 2023

Margo C. Funk, MD, MA, FACLP

Margo C. Funk, MD, MA, FACLP.

Director of Cardiovascular Psychiatry, Vice Chair for Education, Residency Program Director, Department of Psychiatry, Brigham and Women’s Hospital, Boston, MA.

Dr. Funk has disclosed that in 2021, she received fees as a consultant for Acadia Pharmaceuticals. Dr. Aiken has reviewed this educational activity and has determined that there is no commercial bias as a result of this financial relationship.

Most psychiatric meds have cardiac risks. Dr. Funk tells us when to put the brakes on.

Clinical Update

Anorexia: An Update for the Psychopharmacologist

January 31, 2023

Chris Aiken, MD and Garrett Rossi, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.
Garrett Rossi, MD. Adult psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Dr. Aiken and Dr. Rossi have no financial relationships with companies related to this material.

A half-dozen reviews have concluded that no medication is effective for anorexia. We agree, but they may have overlooked a common supplement with evidence to help: Zinc.

EXPERT Q&A

Psychiatric Issues in Organ Transplantation

January 2, 2023

Paula C. Zimbrean, MD, FAPA, FACLP

Paula C. Zimbrean, MD, FAPA, FACLP

Associate professor of psychiatry and surgery (transplant), Yale University School of Medicine; Chair, Transplant Psychiatry Special Interest Group, Academy of Consultation Psychiatry. New Haven, CT.

Dr. Zimbrean has consulted for Ultragenyx and Vivet Therapeutics, and has consulted and advised for Alexion. Relevant financial relationships listed for the author have been mitigated.

Growing numbers of patients receive organ transplants every year. This Q&A reviews the unique considerations that arise when these patients require psychiatric care.

RESEARCH UPDATE

Office-Based Opioid Treatment

October 31, 2022

Joshua Blum MD

Joshua Blum, MD. Dr. Blum, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Some providers may be reluctant to treat patients with opioid use disorders with MOUD, especially in a busy primary care setting, fearing that these patients are “too complex.” In this observational study, investigators found that patients on MOUD are not all that different from everyone else.

Psychopharm Commandment 3: Lithium Toxicity

October 10, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Lithium toxicity: How to avoid it, and what to do when it happens.

EXPERT Q&A

QT Intervals in Psychiatric Practice

October 1, 2022

Victoria Hendrick, MD and Paul Barkopoulos, MD.

Paul Barkopoulos, MD. Clinical Assistant Professor, Psychiatry & Biobehavioral Sciences, UCLA David Geffen School of Medicine and Olive View UCLA Medical Center, Los Angeles, CA.

Victoria Hendrick, MD. Editor-in-Chief, The Carlat Hospital Psychiatry Report; Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Dr. Barkopoulos and Dr. Hendrick, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Several psychiatric medications prolong the QTc interval and place patients at risk of the dreaded torsade de pointes. Some patients are particularly vulnerable to QTc prolongation: the elderly, patients with heart disease and electrolyte imbalances, and patients taking certain medications, like thioridazine and ziprasidone. We provide a step-by-step guide so that you can keep your patients safe from this cardiovascular side effect.

RESEARCH UPDATE

Do White Matter Hyperintensities Predict Memory Loss with Electroconvulsive Therapy?

October 1, 2022

Dax Volle, MD

Dax Volle, MD. Dr. Volle, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

We can continue to recommend ECT to patients with severe white matter hyperintensities and cognitive impairment, as cognition seems to return to baseline following ECT.